Quest Partners LLC Increases Stock Holdings in Myriad Genetics, Inc. (NASDAQ:MYGN)

Quest Partners LLC boosted its position in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 50.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,001 shares of the company’s stock after acquiring an additional 2,697 shares during the quarter. Quest Partners LLC’s holdings in Myriad Genetics were worth $219,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State of New Jersey Common Pension Fund D acquired a new stake in Myriad Genetics in the 3rd quarter valued at about $1,965,000. Legato Capital Management LLC acquired a new stake in Myriad Genetics in the 2nd quarter valued at about $1,123,000. Assenagon Asset Management S.A. raised its position in Myriad Genetics by 26.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 250,524 shares of the company’s stock valued at $6,128,000 after purchasing an additional 52,813 shares in the last quarter. Maven Securities LTD acquired a new stake in Myriad Genetics in the 2nd quarter valued at about $1,223,000. Finally, Tidal Investments LLC acquired a new stake in Myriad Genetics in the 1st quarter valued at about $606,000. 99.02% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Myriad Genetics

In other Myriad Genetics news, Director Heinrich Dreismann sold 10,000 shares of Myriad Genetics stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $27.05, for a total value of $270,500.00. Following the transaction, the director now directly owns 121,648 shares in the company, valued at approximately $3,290,578.40. This trade represents a 7.60 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Paul J. Diaz sold 15,000 shares of Myriad Genetics stock in a transaction that occurred on Friday, October 11th. The shares were sold at an average price of $22.93, for a total value of $343,950.00. Following the completion of the transaction, the chief executive officer now owns 962,378 shares in the company, valued at $22,067,327.54. This trade represents a 1.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 71,012 shares of company stock worth $1,900,485. 2.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MYGN. TD Cowen raised their target price on Myriad Genetics from $28.00 to $30.00 and gave the stock a “hold” rating in a research report on Wednesday, August 7th. Piper Sandler cut their target price on Myriad Genetics from $30.00 to $24.00 and set a “neutral” rating on the stock in a research report on Monday, November 11th. Morgan Stanley cut their target price on Myriad Genetics from $32.00 to $21.00 and set an “equal weight” rating on the stock in a research report on Monday, November 18th. StockNews.com lowered Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Finally, Wells Fargo & Company began coverage on Myriad Genetics in a research report on Tuesday, August 27th. They set an “overweight” rating and a $35.00 target price on the stock. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Myriad Genetics has a consensus rating of “Hold” and a consensus price target of $27.36.

Myriad Genetics Trading Up 0.7 %

MYGN opened at $16.28 on Thursday. The firm has a market cap of $1.48 billion, a price-to-earnings ratio of -12.52 and a beta of 1.93. Myriad Genetics, Inc. has a 52 week low of $14.72 and a 52 week high of $29.30. The business’s 50 day moving average is $21.77 and its two-hundred day moving average is $24.35. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05.

Myriad Genetics Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.